Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2

BACKGROUND: Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2), a phase III study in postmenopausal women with estrogen receptor–positive breast cancer progressing despite nonsteroidal aromatase inhibitor therapy, showed statistically significant benefits with adding everolimus to exemestane. More...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Natl Cancer Inst
Main Authors: Gnant, Michael, Baselga, Jose, Rugo, Hope S., Noguchi, Shinzaburo, Burris, Howard A., Piccart, Martine, Hortobagyi, Gabriel N., Eakle, Janice, Mukai, Hirofumi, Iwata, Hiroji, Geberth, Matthias, Hart, Lowell L., Hadji, Peyman, El-Hashimy, Mona, Rao, Shantha, Taran, Tetiana, Sahmoud, Tarek, Lebwohl, David, Campone, Mario, Pritchard, Kathleen I.
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2013
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6430494/
https://ncbi.nlm.nih.gov/pubmed/23425564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt026
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker